Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
611 questions in 50 reviews · Injuries
current versionsNo studies 125 · 20.5%Ungraded 22 · 3.6%Very low 185 · 30.3%Low 171 · 28%Moderate 77 · 12.6%High 31 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR TXA given intravenously at a total dose of 1 g intraoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid,… Pharmacological interventions for the prevention of bleeding in people undergoing elective hip or knee… (2024) · Cochrane | no estimate extracted | 1 participants | Low |
Intervention NR TXA given intravenously at a total dose of 2 g pre‐incision · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid,… Pharmacological interventions for the prevention of bleeding in people undergoing elective hip or knee… (2024) · Cochrane | no estimate extracted | 2 participants | Moderate |
Intervention NR TXA given intravenously and intra‐articularly at a total dose of 2 g intraoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid,… Pharmacological interventions for the prevention of bleeding in people undergoing elective hip or knee… (2024) · Cochrane | no estimate extracted | 2 participants | Moderate |
Intervention NR TXA given intravenously and orally at a total dose of greater than 3 g pre‐incision and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid,… Pharmacological interventions for the prevention of bleeding in people undergoing elective hip or knee… (2024) · Cochrane | no estimate extracted | 3 participants | Low |
Intervention NR TXA given intravenously at a total dose of 1 g pre‐incision and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid,… Pharmacological interventions for the prevention of bleeding in people undergoing elective hip or knee… (2024) · Cochrane | no estimate extracted | 1 participants | Low |
Intervention NR TXA given intravenously and intra‐articularly at a total dose of greater than 3 g pre‐incision, intraoperatively and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid,… Pharmacological interventions for the prevention of bleeding in people undergoing elective hip or knee… (2024) · Cochrane | no estimate extracted | 3 participants | Low |
Cell salvage vs no cell salvage Transfusions (during hospital stay) ‐ not reported · cancer surgery Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | no estimate extracted | NR | No studies |
Cell salvage vs no cell salvage Mortality (up to 90 days) · cardiovascular (vascular) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | 1.19 [0.39, 3.65] | 6 studies · 384 participants | Very low |
Cell salvage vs no cell salvage DVT (up to 90 days) · cardiovascular (vascular) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | RD 0 | 1 study · 100 participants | Very low |
Cell salvage vs no cell salvage Infection (up to 90 days) · cardiovascular (vascular) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | RR 0.23 [0.03, 1.98] | 2 studies · 117 participants | Very low |
Cell salvage vs no cell salvage MI (up to 90 days) · cardiovascular (vascular) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | 0.76 [0.17, 3.41] | 3 studies · 203 participants | Very low |
Cell salvage vs no cell salvage CVA (stroke) (up to 90 days) · cardiovascular (vascular) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | 0.14 [0, 6.82] | 1 study · 100 participants | Very low |
Cell salvage vs no cell salvage Transfusions (during hospital stay) · cardiovascular (no bypass) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | RR 0.82 [0.69, 0.97] | 3 studies · 169 participants | Moderate |
Cell salvage vs no cell salvage Volume of transfusion (units) (PPT) (during hospital stay) · cardiovascular (no bypass) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | no estimate extracted | 2 studies · 56 participants | Low |
Cell salvage vs no cell salvage Mortality (up to 90 days) · cardiovascular (no bypass) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | 0.13 [0.01, 2.07] | 4 studies · 209 participants | Very low |
Cell salvage vs no cell salvage DVT (up to 90 days) ‐ not reported · cardiovascular (no bypass) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | no estimate extracted | NR | No studies |
Cell salvage vs no cell salvage Infection (up to 90 days) · cardiovascular (no bypass) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | 2.06 [0.21, 20.61] | 2 studies · 110 participants | Very low |
Cell salvage vs no cell salvage Volume (PPT) (during hospital stay) ‐ not reported · cancer surgery Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | no estimate extracted | NR | No studies |
Cell salvage vs no cell salvage MI (up to 90 days) · cardiovascular (no bypass) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | 1.98 [0.2, 19.32] | 2 studies · 120 participants | Very low |
Cell salvage vs no cell salvage CVA (stroke) (up to 90 days) · cardiovascular (no bypass) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | 0.98 [0.06, 15.72] | 3 studies · 160 participants | Very low |
Cell salvage vs no cell salvage Transfusions (during hospital stay) · cardiovascular (with bypass) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | RR 0.81 [0.73, 0.89] | 25 studies · 2676 participants | Low |
Cell salvage vs no cell salvage Volume of transfusion (units) (PPT) (during hospital stay) · cardiovascular (with bypass) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | no estimate extracted | 16 studies · 1264 participants | Very low |
Cell salvage vs no cell salvage Mortality (up to 90 days) · cardiovascular (with bypass) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | RR 0.86 [0.5, 1.48] | 21 studies · 2491 participants | Very low |
Cell salvage vs no cell salvage DVT (up to 90 days) · cardiovascular (with bypass) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | RD 0 | 1 study · 30 participants | Very low |
Cell salvage vs no cell salvage Infection (up to 90 days) · cardiovascular (with bypass) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | RR 1.16 [0.83, 1.61] | 8 studies · 1231 participants | Low |
Cell salvage vs no cell salvage MI (up to 90 days) · cardiovascular (with bypass) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | 0.86 [0.47, 1.58] | 9 studies · 1376 participants | Very low |
Cell salvage vs no cell salvage CVA (stroke) (up to 90 days) · cardiovascular (with bypass) surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | RR 0.54 [0.23, 1.24] | 5 studies · 1018 participants | Moderate |
Cell salvage vs no cell salvage Transfusions (during hospital stay) · obstetric surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | 0.82 [0.38, 1.76] | 1 study · 1349 participants | Low |
Cell salvage vs no cell salvage Mortality (up to 90 days) · cancer surgery Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | RR 0.56 [0.11, 2.8] | 2 studies · 79 participants | Very low |
Cell salvage vs no cell salvage Volume of transfusion (units) (PPT) (during hospital stay) · obstetric surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | no estimate extracted | 1 study · 27 participants | Low |
Cell salvage vs no cell salvage Mortality (up to 90 days) ‐ not reported · obstetric surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | no estimate extracted | NR | No studies |
Cell salvage vs no cell salvage DVT (up to 90 days) ‐ not reported · obstetric surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | no estimate extracted | NR | No studies |
Cell salvage vs no cell salvage Infection (up to 90 days) ‐ not reported · obstetric surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | no estimate extracted | NR | No studies |
Cell salvage vs no cell salvage MI (up to 90 days) ‐ not reported · obstetric surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | no estimate extracted | NR | No studies |
Cell salvage vs no cell salvage CVA (stroke) (up to 90 days) ‐ not reported · obstetric surgeries Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | no estimate extracted | NR | No studies |
Cell salvage vs no cell salvage Transfusions (during hospital stay) · orthopaedic (hip) Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | RR 0.52 [0.38, 0.72] | 14 studies · 1641 participants | Very low |
Cell salvage vs no cell salvage Volume of transfusion (units) (PPT) (during hospital stay) · orthopaedic (hip) Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | no estimate extracted | 4 studies · 63 participants | Very low |
Cell salvage vs no cell salvage Mortality (up to 90 days) · orthopaedic (hip) Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | 0.46 [0.06, 3.33] | 4 studies · 651 participants | Very low |
Cell salvage vs no cell salvage DVT (up to 90 days) · orthopaedic (hip) Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | 1.05 [0.2, 5.6] | 3 studies · 343 participants | Very low |
Cell salvage vs no cell salvage DVT (up to 90 days) · cancer surgery Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | RR 0.5 [0.05, 4.81] | 1 study · 24 participants | Very low |
Cell salvage vs no cell salvage Infection (up to 90 days) · orthopaedic (hip) Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | 0.72 [0.17, 2.98] | 4 studies · 549 participants | Very low |
Cell salvage vs no cell salvage MI (up to 90 days) ‐ not reported · orthopaedic (hip) Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | no estimate extracted | NR | No studies |
Cell salvage vs no cell salvage CVA (stroke) (up to 90 days) · orthopaedic (hip) Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | RR 3 [0.13, 68.26] | 1 study · 30 participants | Very low |
Cell salvage vs no cell salvage Transfusions (during hospital stay) · orthopaedic (knee) Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | RR 0.49 [0.37, 0.66] | 21 studies · 2214 participants | Very low |
Cell salvage vs no cell salvage Volume of transfusion (units) (PPT) (during hospital stay) · orthopaedic (knee) Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | no estimate extracted | 3 studies · 221 participants | Very low |
Cell salvage vs no cell salvage Mortality (up to 90 days) ‐ not reported · orthopaedic (knee) Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | no estimate extracted | NR | No studies |
Cell salvage vs no cell salvage DVT (up to 90 days) · orthopaedic (knee) Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | 1.29 [0.56, 2.95] | 9 studies · 793 participants | Very low |
Cell salvage vs no cell salvage Infection (up to 90 days) · orthopaedic (knee) Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | 0.74 [0.28, 1.94] | 5 studies · 730 participants | Very low |
Cell salvage vs no cell salvage MI (up to 90 days) · orthopaedic (knee) Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | 7.02 [0.14, 354.4] | 1 study · 115 participants | Very low |
Cell salvage vs no cell salvage CVA (stroke) (up to 90 days) · orthopaedic (knee) Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery (2023) · Cochrane | RD 0 | 1 study · 60 participants | Low |